TABLE 3.
Oligonucleotide primer used in gene amplifications and hybrid constructions
| Name | 5′→3′ oligonucleotide sequencea | Restriction site(s) |
|---|---|---|
| DSBC-1 | ACC ACC ATG GAT GAC GCG GCG ATC AAA CAG GCG CTG | NcoI |
| DSBC-2 | AGC ACA AGC TTC CAT TAG CCG CCT GAT TTC AGC GAG | HindIII |
| PSE-2801 | CCG GCC CGT ATA ATG TGT GG | None |
| PSE-2802 | CAG ACC GCT TCT GCG TTC TG | None |
| POLYG | A TTA CTG CAG GCC GGC GGC ACC GAC ACC TTC GAC TTC TCC | PstI-NaeI |
| POLYG-2 | ATT ACC ATT GCA CCC GGG GGC ACC GAC ACC TTC GAC TTC TCC | SmaI |
| PRTB-4 | TC GCG AAG CTT TTA CAC AAT AAT ATC GGA TTG GCG | HindIII |
| CHIT-1 | AAC ACC ATG GCC CAG GCC ACT CTC ATT TCT GCA TCT CCT | NcoI |
| CHIT-4 | AAA CCG CGG TTA GCC GGC GTT GAG ACC GCT TCG GAT GTT ATC ATA CTG | SstI, NaeI |
| GFPNH-3 | C GCC AAG CTT GCA TGC CTG CAG GTC GAC TCT AGA | HindIII |
| GFPCT-4 | G GTA CCC GGG TTT GTA TAG TTC ATC CAT GCC ATG TG | SmaI |
| OC-1 | AG CCC CGG GCC ATG GAA ATT TAT AAT AAA GAC GGC AAC AAA TTA | NcoI |
| OC-51 | A ATA CCC GGG AGC GGT GTT GTT CTG ATC GGC AGT ACG TTT AG | SmaI |
| EPO-1 | T AGG ACC ATG GCG CCA CCA CGC CTG ATC TGT GAC AGC | NcoI |
| EPO-2 | T TAG GAT ATC TCG GTC CCC TGT CCG GCA GGC CTC CCC | EcoRV |
| TGH-21 | A TGA CCC ATG GAA AAC CAA CGT CTC TTC AAC ATC | NcoI |
| TGH-22 | G GCC GAT ATC CAG AGT GCA GTT GGC CTC CAG TGA | EcoRV |
a
Oligonucleotides were synthesized by Synthaid Biotechnology Inc., Ottawa, Canada. In all cases, signal peptide sequences were excluded in the primer design to avoid the use of a peptide signal-dependent secretion system during hybrid secretion evaluation. Restriction sites included in the oligonucleotides are underlined.